Richter Gedeon Vegyeszeti Gyar Nyrt banner
R

Richter Gedeon Vegyeszeti Gyar Nyrt
XMUN:RIG2

Watchlist Manager
Richter Gedeon Vegyeszeti Gyar Nyrt
XMUN:RIG2
Watchlist
Price: 30.56 EUR
Market Cap: €5.7B

RIG2's latest stock split occurred on Jul 11, 2013

The company executed a 10-for-1 stock split, meaning that for every share held, investors received 10 new shares.

Before the split, RIG2 traded at 12.164 per share. Afterward, the share price was about 999999.9999.

The adjusted shares began trading on Jul 11, 2013. This was the only stock split in RIG2's history.

Last Splits:
Jul 11, 2013
10-for-1
Pre-Split Price
999 999.9999 12.164
Post-Split Price
999 999.9999
Before
After
Last Splits:
Jul 11, 2013
10-for-1

Richter Gedeon Vegyeszeti Gyar Nyrt
Stock Splits History

RIG2 Stock Splits Timeline
Jul 11, 2013
Jul 11, 2013
Split 10-for-1
x10
Pre-Split Price
999 999.9999 12.164
Post-Split Price
999 999.9999
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Mar 27, 2026
L
Li Bang International Corporation Inc
NASDAQ:LBGJ
1-for-100
/100
0.0103 1.03 USD 0.9329 0.9329 USD
Mar 27, 2026
Hind Rectifiers Ltd
NSE:HIRECT
2-for-1
x2
1588 794 INR 717.4 717.4 INR
Mar 27, 2026
K
Konecranes Abp
OTC:KNCRF
3-for-1
x3
99.5 33.1667 USD 32.6325 32.6325 USD
Mar 27, 2026
S
Sanyu Construction Co Ltd
TSE:1841
1-for-92100
/92100
1590 1590 JPY N/A
Mar 27, 2026
Advantage Solutions Inc
NASDAQ:ADV
1-for-25
/25
0.903 22.575 USD 25.57 25.57 USD
Load More

Richter Gedeon Vegyeszeti Gyar Nyrt
Glance View

Richter Gedeon Vegyeszeti Gyar Nyrt., popularly known as Gedeon Richter, traces its origins to 1901, when its founder, Gedeon Richter, established a modest pharmacy on the outskirts of Budapest. With a deep passion for innovation and a forward-thinking mindset, Richter transformed his small endeavor into Hungary's pioneering pharmaceutical company. Today, Gedeon Richter stands as a significant player in the global pharmaceutical industry, excelling in the research, development, manufacturing, and marketing of a wide array of medicinal products. The company's emphasis on in-house innovation and strategic collaborations has enabled it to carve a niche in the field of women's healthcare, biotechnology, and central nervous system therapies. The heart of Gedeon Richter's operations lies in its robust research and development capabilities. By investing heavily in scientific excellence, the company has developed a diversified portfolio that includes generic and specialty pharmaceuticals, as well as original research-driven products. The company generates revenue through a network that spans more than 100 countries, with a strong presence in Europe, the Commonwealth of Independent States, and the global markets at large. By keeping its manufacturing processes vertically integrated and maintaining a comprehensive distribution network, Gedeon Richter not only ensures efficiency and cost-effectiveness, but also consistently delivers quality products to both niche markets and mass consumers. This strategic focus on sustainable growth, combined with its commitment to providing innovative healthcare solutions, reflects the synergy of past legacy with future-focused aspirations.

RIG2 Intrinsic Value
42.67 EUR
Undervaluation 28%
Intrinsic Value
Price
R
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett